Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs TTM Technologies Inc. Common Stock (TTMI) Price & Performance

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.

TTMI trades at $116.10, up 5.23% today, but faces a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong revenue growth is projected, from $2.9B in 2025 to $3.4B in 2026, alongside a rising net profit margin. A significant $1.7B defense backlog and expansion in AI data-center demand support the growth narrative, though the stock's valuation multiples appear elevated.

The outlook is mixed; robust fundamentals and overwhelming analyst buy ratings (85.7%) suggest long-term potential, with a consensus price target of $203.67 implying substantial upside. However, near-term technical weakness and high valuation ratios relative to profitability metrics present risks, requiring careful monitoring of execution against growth expectations.